Sign in
NRSNW Stock Price, Chart, Stats & News
NeuroSense Therapeutics Ltd.
Save
NeuroSense Therapeutics Ltd. (NRSNW) does not currently pay a dividend.
2.22M
Market cap
–
Current P/E
–
Forward P/E
NRSNW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -514.13% |
ROE | 2720.50% |
D/E | – |
Interest coverage ratio | -97.39x |
NRSNW valuation
P/E | – |
P/S | – |
P/B | -35.78x |
P/CF | -9284.43x |
P/FCF | -9015.67x |
P/OCF | -9284.43x |
PEG | 0.14x |
EV multiple | -2.19x |
About
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease.
Similar securities
Based on sector and market capitalization
Report issue